The earnings call highlighted significant progress in clinical trials and partnerships, particularly with AstraZeneca, alongside financial stability and leadership enhancements. However, ongoing arbitration with Servier and a decrease in cash reserves present challenges.

Company Guidance -

Q3 2025

During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key areas. Cellectis announced the initiation of a pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia, following productive discussions with the FDA and EMA. They anticipate having clinical trial sites open for recruitment by the end of the year, with additional data submitted for consideration at the ASH Annual Conference in Q4. The company also discussed ongoing research under their AstraZeneca partnership, covering three cell and gene therapy programs. Financially, Cellectis reported cash and equivalents of $230 million as of June 30, 2025, sufficient to fund operations into H2 2027. They are awaiting an arbitral decision in their dispute with Servier, expected by December 15, 2025, which could impact their financial position depending on the outcome. The company also highlighted an upcoming Investors R&D Day on October 16, 2025, where they will present detailed data from their clinical trials and discuss future strategies.

Initiation of Pivotal Phase II Trial for Lasme-cel

Cellectis is preparing for the initiation of a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025.

Successful End of Phase I Discussions

Cellectis completed end of Phase I discussions with both the FDA and EMA, receiving productive feedback and clear paths for further clinical trials.

Partnership Progress with AstraZeneca

Ongoing research and development activities under the Joint Research and Collaboration Agreement with AstraZeneca across three cell and gene therapy programs.

Financial Stability

Cellectis has sufficient cash to fund operations into H2 2027, with $230 million in cash, cash equivalents, and fixed-term deposits as of June 30, 2025.

Appointment of New Board Member

Mr. André Muller was appointed to Cellectis' Board of Directors, bringing extensive experience to the company.

Cellectis SA (CLLS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLLS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.23 / -	-0.23	―	―	―
Aug 04, 2025	2025 (Q2)	-0.21 / -0.24	-0.28	14.29% (+0.04)	―
May 12, 2025	2025 (Q1)	-0.15 / -0.18	0.08	-325.00% (-0.26)	―	―
Mar 13, 2025	2024 (Q4)	-0.18 / -0.17	-0.64	73.44% (+0.47)	―
Nov 04, 2024	2024 (Q3)	-0.20 / -0.23	-0.31	25.81% (+0.08)	―
Aug 06, 2024	2024 (Q2)	-0.29 / -0.28	-0.19	-47.37% (-0.09)	―	―
May 28, 2024	2024 (Q1)	-0.33 / 0.08	-0.58	113.79% (+0.66)	―
Mar 11, 2024	2023 (Q4)	-0.21 / -0.08	-0.59	86.10% (+0.51)	―	―
Nov 06, 2023	2023 (Q3)	-0.42 / -0.31	-0.63	50.79% (+0.32)	―
Aug 03, 2023	2023 (Q2)	-0.44 / -0.19	-0.42	54.76% (+0.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLLS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$3.02	$2.53	-16.23%
May 12, 2025	$1.51	$1.41	-6.62%
Mar 13, 2025	$1.29	$1.24	-3.88%
Nov 04, 2024	$1.76	$1.78	+1.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cellectis SA (CLLS) report earnings?

Cellectis SA (CLLS) is schdueled to report earning on Nov 10, 2025, TBA (Confirmed).

What is Cellectis SA (CLLS) earnings time?

Cellectis SA (CLLS) earnings time is at Nov 10, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CLLS EPS forecast?

CLLS EPS forecast for the fiscal quarter 2025 (Q3) is -0.24.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing